loading
전일 마감가:
$8.00
열려 있는:
$8.4
하루 거래량:
7,739
Relative Volume:
1.89
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+11.35%
1개월 성능:
+20.85%
6개월 성능:
-9.58%
1년 성능:
+0.00%
1일 변동 폭
Value
$8.40
$10.00
1주일 범위
Value
$7.70
$10.00
52주 변동 폭
Value
$2.60
$14.67

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Name
명칭
Newamsterdam Pharma Company N V
Name
전화
31 35 206 2971
Name
주소
Gooimeer 2-35, Naarden
Name
직원
22
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
NAMSW's Discussions on Twitter

Newamsterdam Pharma Company N V 주식(NAMSW)의 최신 뉴스

pulisher
Nov 03, 2024

(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 01, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024
pulisher
Oct 28, 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - 24matins.uk

Oct 28, 2024
pulisher
Oct 25, 2024

Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

Oct 25, 2024
pulisher
Oct 18, 2024

NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia

Oct 18, 2024
pulisher
Oct 18, 2024

NewAmsterdam Pharma to Restate Prior Financials - Investing.com India

Oct 18, 2024
pulisher
Oct 17, 2024

(NAMSW) Trading Report - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 14, 2024

NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq

Oct 14, 2024
pulisher
Oct 12, 2024

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat

Oct 12, 2024
pulisher
Oct 11, 2024

NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11 - MSN

Oct 11, 2024
pulisher
Oct 11, 2024

Marshall Wace LLP Decreases Stake in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Oct 11, 2024
pulisher
Oct 07, 2024

When the Price of (NAMSW) Talks, People Listen - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 05, 2024

Millennium Management LLC Has $22.39 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha

Oct 04, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma executive sells shares worth $707,400 By Investing.com - Investing.com South Africa

Oct 01, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma executive sells shares worth $707,400 - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $16.60 - MarketBeat

Oct 01, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma Company NV (NAMS) rating initates by TD Cowen - Knox Daily

Oct 01, 2024
pulisher
Oct 01, 2024

Does NewAmsterdam Pharma Company NV (NAMS) offer a good opportunity for investors? - SETE News

Oct 01, 2024
pulisher
Sep 30, 2024

Newamsterdam Pharma exec buys $17,332 in company stock By Investing.com - Investing.com Australia

Sep 30, 2024
pulisher
Sep 30, 2024

Newamsterdam Pharma exec buys $17,332 in company stock - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume - MarketBeat

Sep 30, 2024
pulisher
Sep 29, 2024

TD Cowen Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

Sep 29, 2024
pulisher
Sep 26, 2024

Deerfield Management Company L.P. Series C Has $16.70 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Affinity Asset Advisors LLC Boosts Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Sep 25, 2024
pulisher
Sep 23, 2024

Investment opportunity in NewAmsterdam Pharma stock as anticipation builds for BROADWAY results By Investing.com - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Overweight" Rating from Piper Sandler - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Expert Ratings For NewAmsterdam Pharma - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

Piper sees ‘attractive buying opportunity’ into NewAmsterdam data - TipRanks

Sep 23, 2024
pulisher
Sep 23, 2024

NWF Group Shareholding Structure Altered - TipRanks

Sep 23, 2024
pulisher
Sep 21, 2024

'She's A Hardy Filly': Ocean Club Goes All The Way On Front End In Noble Damsel - Paulick Report

Sep 21, 2024
pulisher
Sep 21, 2024

Ocean Club Skims to Narrow Victory in Noble Damsel - BloodHorse.com

Sep 21, 2024
pulisher
Sep 21, 2024

Ocean Club, in quick turnaround, holds off Five Towns, Breath Away to take Noble Damsel - Daily Racing Form

Sep 21, 2024
pulisher
Sep 21, 2024

Trend Tracker for (NAMS) - Stock Traders Daily

Sep 21, 2024
pulisher
Sep 20, 2024

Top Bud padlocked in Holland Patent for illegal cannabis - Rome Sentinel

Sep 20, 2024
pulisher
Sep 20, 2024

Kenneth Law, who sold poisonous chemical linked to 131 deaths, sued by Ontario teen's parents - CBC.ca

Sep 20, 2024
pulisher
Sep 17, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Sep 17, 2024
pulisher
Sep 07, 2024

While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership - Yahoo Finance

Sep 07, 2024
pulisher
Sep 05, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat

Sep 05, 2024
pulisher
Sep 01, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Up 20.7% in August - MarketBeat

Sep 01, 2024
pulisher
Aug 30, 2024

NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan

Aug 30, 2024
pulisher
Aug 30, 2024

Buying Buzz: NewAmsterdam Pharma Company NV [NAMS] Chief Executive Officer Davidson Michael H. purchases 5,000 shares of the company – Knox Daily - Knox Daily

Aug 30, 2024
pulisher
Aug 30, 2024

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - Yahoo Finance

Aug 30, 2024
pulisher
Aug 29, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - MarketBeat

Aug 29, 2024
pulisher
Aug 28, 2024

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Benzinga

Aug 28, 2024
pulisher
Aug 28, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at Needham & Company LLC - MarketBeat

Aug 28, 2024
pulisher
Aug 27, 2024

NewAmsterdam shares hold Buy rating on strong trial data - Investing.com

Aug 27, 2024
pulisher
Aug 27, 2024

NewAmsterdam Pharma Company NV (NAMS)’s Market Momentum: Closing Strong at 16.76, Up 3.08 - The Dwinnex

Aug 27, 2024
pulisher
Aug 26, 2024

You might want to take a look at NewAmsterdam Pharma Company NV (NAMS) now - SETE News

Aug 26, 2024
pulisher
Aug 23, 2024

The Future of NewAmsterdam Pharma Company NV: Analyzing NAMS - The InvestChronicle

Aug 23, 2024
pulisher
Aug 23, 2024

NewAmsterdam Pharma Company NV [NAMS] is 47.99% higher this YTD. Is it still time to buy? - The DBT News

Aug 23, 2024

Newamsterdam Pharma Company N V (NAMSW) 재무 분석

Newamsterdam Pharma Company N V (NAMSW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$22.79
price up icon 1.03%
$75.22
price down icon 1.25%
$376.08
price up icon 0.50%
$54.26
price down icon 0.74%
$207.51
price up icon 1.32%
$108.16
price down icon 3.03%
자본화:     |  볼륨(24시간):